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http://www.ojrd.com/content/9/1/16RESEARCH Open AccessEvidence-based practice in Behçet’s disease:
identifying areas of unmet need for 2014
Robert J Barry1,2, Bharat Markandey3, Rahul Malhotra3, Henry Knott3, Nikita Joji3, Mohammed Mubin3,
Alastair K Denniston1,2,4,5* and Phillip I Murray1,2,5Abstract
Background: Behçet’s Disease (BD) is characterized by a relapsing-remitting course, with symptoms of varying
severity across almost all organ systems. There is a diverse array of therapeutic options with no universally accepted
treatment regime, and it is thus important that clinical practice is evidence-based. We reviewed all currently
available literature describing management of BD, and investigated whether evidence-based practice is possible
for all disease manifestations, and assessed the range of therapeutic options tested.
Methods: We conducted an internet search of all literature describing management of BD up to August 2013,
including pharmacological and non-pharmacological interventions. We recorded treatment options investigated
and disease manifestations reported as primary and secondary study outcomes. Quality of data was assessed
according to the Scottish Intercollegiate Guideline Network (SIGN) hierarchy of evidence.
Results: Whilst there is much literature describing treatment of ocular and mucocutaneous disease, there is little to
guide management of rheumatoid, cardiovascular and neurological disease. This broadly reflects the prevalence
of disease manifestations of BD, but not the severity. Biologic therapies are the most commonly investigated
intervention. The proportion of SIGN-1 graded studies is declining, and there are no SIGN-1 graded studies
investigating neurological or gastrointestinal manifestations of BD.
Conclusions: This is the first study to investigate trends in published literature for management of BD over time. It
identifies neurological, cardiovascular and gastro-intestinal disease as particular areas of unmet need and suggests
that overall quality of evidence is declining. Future research should be designed to address these areas of
insufficiency to facilitate evidence-based practice in BD.
Keywords: Behçet’s disease, Evidence based medicine, Therapy, Systematic reviewBackground
To achieve optimum patient outcomes, clinicians must
strive to practice evidence-based medicine wherever pos-
sible. Evidence-based practice has two requirements: the
availability of published research [1], and the ability to
critically appraise the information presented [2].
Decisions regarding treatment should thus be in-
formed by the experience of others, as presented in
peer-reviewed medical and scientific journals. Clinicians* Correspondence: a.denniston@bham.ac.uk
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Infection, College of Medical and Dental Sciences, Queen Elizabeth Hospital,
University of Birmingham, B15 2TT Birmingham, UK
2Academic Unit of Ophthalmology, University of Birmingham, Birmingham
and Midland Eye Centre, City Hospital, Birmingham, UK
Full list of author information is available at the end of the article
© 2014 Barry et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.must however be aware of bias and inaccuracy, and be
prepared to question such literature. Publication does
not guarantee quality, and there is a hierarchy of evi-
dence ranging from that derived through expert opinion
and case report, to that supported by large-scale ran-
domized controlled trials [3].
This is particularly important for the management of
rare diseases, where there may not be a widely-accepted
“gold-standard” treatment, and also in complex multi-
system diseases, where there are likely to be a range of
potential treatment options depending on the presenting
features. Behçet’s Disease (BD) is both rare and complex:
is a multi-system inflammatory disorder of unknown
aetiology [4], with an estimated incidence of 0.64 per
100,000 people in the UK and 5.2 per 100,000 in the USA.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Scottish Intercollegiate Guideline Network (SIGN)
grading of evidence, with equivalent simplified
categorization used for present analysis
Level of
evidence
Description Categorisation
in this analysis
1++ High quality meta-analyses, systematic
reviews of RCTs, or RCTs with a very low
risk of bias
1
1+ Well conducted meta-analyses, systematic
reviews of RCTs, or RCTs with a low risk
of bias
1− Meta-analyses, systematic reviews or RCTs,
or RCTs with a high risk of bias
2++ High quality systematic reviews of
case-control or cohort studies or High
quality case-control or cohort studies with
a very low risk of confounding, bias, or
chance and a high probability that the
relationship is causal
2
2+ Well conducted case-control or cohort
studies with a low risk of confounding,
bias, or chance and a moderate probability
that the relationship is causal
2− Case-control or cohort studies with a high
risk of confounding, bias, or chance and a
significant risk that the relationship is
not causal
3 Non-analytic studies, e.g. case reports,
case series
3
4 Expert opinion 4
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Far Eastern countries along the historic “Silk Route”, with
disease incidence in Turkey between 20 and 421 per
100,000 people [5].
Patients display a diverse spectrum of symptoms, both
in terms of organ system affected and also the severity
of disease in each of these systems [6]. As a result,
disease management is variable with therapeutic options
ranging from symptomatic relief through to systemic im-
munosuppression [7,8]. Treatment is usually instigated
and monitored by a multi-disciplinary team, involving
collaboration between dermatologists, ophthalmologists
and rheumatologists, with input by cardiologists, genito-
urinary physicians and neurologists as required.
It follows that best practice in BD demands a large
body of supporting literature; it is important that each
member of the multi-disciplinary team has access to up-
to-date evidence to guide their management, with sup-
porting data for each potential disease manifestation, at
varying degrees of severity.
We set out to investigate the scope and quality of the
evidence-base available to clinicians involved in the
management of BD, paying particular attention to how
this literature has evolved over time. We were keen to
determine if it is possible to practice evidence-based
medicine for all potential disease manifestations and
through review of observed trends to identify any areas
of unmet need, to guide further research in this area.
This was achieved through a comprehensive review of
all available peer-reviewed literature, assessing the range
of therapeutic options investigated, the disease manifes-
tations for which these investigations were performed
and the overall quality of the resulting research.
Methods
A systematic online literature search was performed
using the PubMed database, Medline, EMBASE and
the Cochrane Central Register of Controlled Trials
(CENTRAL) for all studies published before August 2013
combining the terms “therapy OR therapeutic OR treat-
ment”, “behçet*” (exploded), and all publication types
relating to clinical trials as listed in the PubMed database.
To be considered for further review, studies were
assessed against strict inclusion and exclusion criteria;
for inclusion, all documented cases of BD must have
been diagnosed according to the International Study
Group (ISG) guidelines (1990) [9], or for those studies
recruiting patients prior to the publication of these
guidelines, diagnosis of BD must have been deemed con-
cordant with ISG criteria by all authors of this review.
Furthermore, the study must have been directly con-
cerned with a therapeutic intervention. Both pharmaco-
logical and non-pharmacological interventions were
included in the review.Publications were excluded if the intervention group
comprised fewer than 20 patients with ISG-confirmed
BD, or if the study did not directly assess a therapeutic
option. Duplicates, narrative reviews and editorials were
excluded from further analysis. Due to the native lan-
guage of the reviewers, we were unable to assess studies
without an English language translation. Since our aim
was to assess the range of data currently available, previ-
ous meta-analyses and systematic reviews were also
excluded from the quantitative analysis.
Data extracted comprised date of publication, number
of patients with ISG-confirmed BD, disease manifesta-
tions investigated and whether this was as a primary or
secondary study outcome, and therapeutic intervention
(s) assessed. Quality was assessed in accordance with the
Scottish Intercollegiate Grading Network (SIGN) hier-
archy of evidence grading for published literature [3],
using a simplified categorization as indicated in Table 1.
Data was entered into a Microsoft Excel spreadsheet for
coding and further analysis.Results
The initial search identified 255 papers, of which 60 met
the above criteria for further review (Table 2). Most
studies were excluded due to small sample size.
Table 2 List of papers included in analysis, arranged in date order (most recent first) with PubMed PMID reference
numbers
Title Published PubMed PMID
[10] Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis 2013 23314623
[11] Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials 23290985
[12] Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of
infliximab therapy
2012 23053631
[13] Multicenter study of infliximab for refractory uveoretinitis in Behçet disease 22652845
[14] A single infliximab infusion vs corticosteroids for acute panuveitis attacks in Behçet’s disease: a comparative
4-week study
2011 21097877
[15] One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological
Behçet’s disease refractory to standard immunosuppressive drugs
19859715
[16] Azathioprine in severe uveitis of Behçet’s disease 2010 20665749
[17] Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease 20545993
[18] Effects of atorvastatin and lisinopril on endothelial dysfunction in patients with Behçet’s disease 20704623
[19] Pimecrolimus versus placebo in genital aphthous ulcers of Behcet’s disease: a randomized double-blind
controlled trial
20704622
[20] Rituximab in intractable ocular lesions of Behcet’s disease; randomized single-blind control study (pilot study) 19692382
[21] Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial 2009 19076988
[22] Effectiveness and safety of endovascular aneurysm treatment in patients with vasculo-Behçet disease 19717547
[23] Low-dose natural human interferon-alpha lozenges in the treatment of Behçet’s syndrome 19842735
[24] Randomized trial of pimecrolimus cream plus colchicine tablets versus colchicine tablets in the treatment of
genital ulcers in Behçet’s disease
19434815
[25] Relationship between periodontal parameters and Behçet’s disease and evaluation of different treatments for oral
recurrent aphthous stomatitis
19320802
[26] The close association between dental and periodontal treatments and oral ulcer course in behcet’s disease: a
prospective clinical study
19060462
[27] Treatment with levamisole and colchicine can result in a significant reduction of IL-6, IL-8 or TNF-α level in
patients with mucocutaneous type of Behcet’s disease
19597921
[28] Behçet’s disease: comparing 3 decades of treatment response at the National Eye Institute 2008 18929351
[29] Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Behçet disease 18711463
[30] Interrelated modulation of endothelial function in Behcet’s disease by clinical activity and corticosteroid treatment 2007 17845731
[31] A double-blind trial of depot corticosteroids in Behçet’s syndrome 2006 17067433
[32] Lactobacilli lozenges in the management of oral ulcers of Behçet’s syndrome 16923135
[33] Oral zinc sulfate in the treatment of Behcet’s disease: a double blind cross-over study 16263779
[34] Colchicine and benzathine penicillin in the treatment of Behçet disease: a case comparative study 2005 16409899
[35] Short-term trial of etanercept in Behçet’s disease: a double blind, placebo controlled study 16321889
[36] Vitrectomy for persistent panuveitis in Behçet’s disease 15630733
[37] Abdominal aortic aneurysm in Behçet’s disease: new treatment options for an old and challenging problem 2004 15079762
[38] Differential efficacy of human recombinant interferon-α2a on ocular and extraocular manifestations of behçet
disease: results of an open 4-center trial
14996689
[39] Infliximab for recurrent, sight-threatening disease in Adamantiades-Behcet disease 15055270
[40] Clinical study on therapeutic effect of acupuncture on Behcet’s disease 2003 14719295
[41] Efficacy of rebamipide as adjunctive therapy in the treatment of recurrent oral aphthous ulcers in patients with
Behçet’s disease: a randomised, double-blind, placebo-controlled study
12928692
[42] Evaluation of the effect of acetazolamide on cystoid macular oedema in patients with Behcet’s disease 12918754
[43] Dapsone in Behçet’s disease: a double-blind, placebo-controlled, cross-over study 2002 12568631
[44] A double-blind trial of colchicine in Behçet’s syndrome 2001 12081158
[45] Mycophenolate mofetil is ineffective in the treatment of mucocutaneous Adamantiades-Behçet’s disease 11935432
[46] Short-term chlorambucil for refractory uveitis in Behcet’s disease 11710724
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Table 2 List of papers included in analysis, arranged in date order (most recent first) with PubMed PMID reference
numbers (Continued)
[47] Ciclosporin Microemulsion Preconcentrate Treatment of Patients With Behçet’s Disease 1999 11752821
[48] Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis
factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet’s disease
10482480
[49] The Use of Sucralfate Suspension in the Treatment of Oral and Genital Ulceration of Behchet Disease 10328192
[50] Thalidomide in the Treatment of the Mucocutaneous Lesions of the Behcet Syndrome 1998 10651074
[51] Treatment of Adamantiades-Behçet disease with systemic interferon alfa 9722733
[52] Effect of prophylactic benzathine penicillin on mucocutaneous symptoms of Behçet’s disease 1996 9499327
[53] Interferon alfa-2a in the treatment of Behçet’s disease 8829493
[54] A phase II study of FK506 (tacrolimus) on refractory uveitis associated with Behçet’s disease and allied conditions 1995 8594659
[55] Inefficacy of azapropazone in the acute arthritis of Behçet’s syndrome: a randomized, double blind, placebo
controlled study
7586783
[56] Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions
such as Behçet’s disease: use of neurophysiological studies to detect thalidomide neuropathy
1994 7864692
[57] Systemic interferon alpha 2b treatment in Behçet’s syndrome 7932420
[58] Visual prognosis in patients with Behçet’s disease receiving colchicine, systemic corticosteroid or cyclosporin 7970549
[59] Low dose cyclosporin A versus pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial 1992 1390495
[60] Desensitization by autologous saliva and Behçet’s disease 1991 1913022
[61] Effect of cyclosporine A on the hearing loss in Behçet’s disease 1771312
[62] Inefficacy of Topical Alpha Interferon in the Treatment of Oral Ulcers of Behcet’s Syndrome: a Randomized
Double Blind Trial
2058987
[63] Long-term effects of cyclophosphamide and colchicine treatment in Behçet’s disease 2064258
[64] Treatment of Behçet disease with indomethacin 1993568
[65] A controlled trial of azathioprine in Behcet’s syndrome 1990 2404204
[66] Topical alpha interferon in the treatment of oral ulcers in Behçet’s syndrome: a preliminary report 2189624
[67] Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in behcet’s disease 1989 2566048
[68] Evaluation of conventional therapy versus cyclosporine A in Behçet’s syndrome 1988 3044474
[69] Treatment with aciclovir does not affect orogenital ulcers in Behcet’s syndrome: a randomised double-blind trial 3381269
Full list of references included at end of main text [10-69].
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mucocutaneous manifestations of disease were the most
frequently reported primary outcomes (27 and 26 studies
respectively), with far fewer studies reporting on cardiovas-
cular, neurological or rheumatological outcomes (Table 3).
Two studies were primarily concerned with quality of life
measures, and two with serological markers of disease withTable 3 Outcomes of studies included in review, stratified
by primary and secondary measures
Disease
manifestation
Number of studies
Primary outcome Secondary outcome
Ocular 27 2
Mucocutaneous 26 5
Rheumatoid 8 8
Cardiovascular 4 5
Neurological 2 5
Other 4 6no symptomatic correlation. Eight studies (13.33%) re-
ported on a range of disease manifestations as primary
outcomes.
These studies represent an overall sample size of 4302
patients with BD, of which 1555 were involved in studies
reporting on ocular outcomes, 1420 mucocutaneous out-
comes, 1144 cardiovascular outcomes, 449 rheumatological
outcomes, 56 neurological, and 109 other outcomes.
The most commonly reported secondary outcome was
rheumatological disease, being assessed in eight studies,
with mucocutaneous disease, cardiovascular and neuro-
logical disease each being reported as secondary out-
come in a further five studies.
A total of 37 distinct therapeutic interventions were
assessed, which were categorized as shown in Table 4.
Most studies investigated pharmacological agents, with
only six studies investigating non-pharmacological inter-
ventions (ocular surgery, retinal laser, cardiovascular
surgery, interventional radiology, dental hygiene and
dental surgery).
Table 4 Interventions assessed by studies included in
review
Intervention Number of studies
Biologic 20
Corticosteroid 8
Antiproliferative 5
Alkylating agent 4
Calcineurin antagonist 12
Other immune modulator 12
NSAID 2
Anti-bacterial 4
Drug acting on cardiovascular systema 2
Other pharmacological interventionb 5
Non-pharmacological interventionc 6
aACEI and statins.
bAutologous saliva, lactobacilli lozenges, rebamipide, sucralfate, zinc sulphate.
cOcular surgery/laser, cardiovascular surgery/laser, dental surgery/hygiene.
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crease in the number of publications reporting on ocular
and mucocutaneous disease manifestations as primary
outcome measures. During this period, there has been a
slower increase in the number of studies reporting on
rheumatological disease as primary outcome and little
increase in the number of studies reporting on all other
manifestations (Figure 1).
Since 2007 there has been a significant increase in the
number of studies investigating biologic therapies for
manifestations of BD (Figure 2). The most significant in-
crease has been in those studies reporting on ocular
manifestations as primary outcome, for which the cumu-
lative number of studies has increased by 140% since
2009 (Figure 3).
According to the SIGN grading for hierarchy of evi-
dence [3], the highest quality research has been conductedFigure 1 Disease manifestation reported as primary study outcome 1for studies reporting on mucocutaneous disease manifes-
tations as primary outcome, followed by those investigat-
ing rheumatological outcomes, then ocular outcomes.
There are currently no high quality controlled trials of
therapy for neurological consequences of BD (Figure 4).
There has been a relative decline in the number of
SIGN-1 graded studies being published since 2010, com-
pared to a relative increase in lower-quality grade 2 and
3 studies (Figure 5).
Discussion
Evidence-based practice demands continuous reappraisal of
peer-reviewed literature, and clinicians must be prepared to
update treatment guidelines as new therapies are validated.
To achieve this, it is useful to assess the scope of published
data, both to review those disease manifestations and treat-
ment modalities that have been thoroughly investigated,
and identify any which may have been neglected. Through
review of current trends in published research we can
predict how the situation is likely to evolve over time and
identify areas of unmet need for future investigation.
This report represents the first such assessment of
trends over time in published literature for the manage-
ment of BD. We have reviewed the available data with
respect to disease manifestations investigated, thera-
peutic interventions tested and have made an assessment
of the quality of this evidence.
We conclude that whilst there is a wealth of published
literature available to guide evidence-based practice in
BD, there are still worrying gaps in the evidence:
In our analysis, mucocutaneous and ocular manifesta-
tions were the most commonly reported primary out-
comes, followed by rheumatological disease, with very few
studies reporting on neurological or cardiovascular symp-
toms as primary outcome. These proportions reflect the
prevalence of each manifestation in the patient population;988-2013.
Figure 2 Therapeutic intervention assessed 1988-2013.
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almost all patients, ocular involvement in up to 69%, joint
involvement in up to 59%, vascular involvement in up to
38% and central nervous system involvement in up to 20%
of patients with BD [6]. It could thus be reasoned that
“supply” of literature is largely matched to “demand”.
Review of publication trends over time suggests that
whilst the number of studies reporting ocular manifesta-
tions as primary outcome are increasing, there have
been no new publications using mucocutaneous mani-
festations as primary outcome since 2009, and none
using rheumatological manifestations as primary out-
come since 1998. Extrapolating these trends forwards,
this suggests a “plateau” in new data generation for
certain aspects of disease, with little new data likely to
appear in the foreseeable future.
Furthermore, whilst mucocutaneous disease is indeed the
most common manifestation of BD, it is the cardiovascularFigure 3 Use of biologic therapy 1988-2013, stratified by disease manand neurological disease which has the potential to be most
serious [5]. Currently, the ability to make evidence-based
treatment decisions for neurological and cardiovascular
disease manifestations is severely limited by a lack of data,
with only four studies employing cardiovascular disease as
primary outcome and two neurological disease.
We found no literature to guide interventions in the
management of gastro-intestinal disease. This has pre-
viously been documented [70] and we find no evidence
of changing practice in this area.
The current trend in the types of therapeutic agent
assessed reveals a bias towards newer, biologic therapies,
with a relative over-representation of studies testing bio-
logics in ocular disease. Again, this reflects the relative
frequency and severity of ocular manifestations in BD.
There is a paucity of studies at the highest levels of
scientific evidence with over-representation of SIGN-2
and SIGN-3 graded papers. This is particularly noticeableifestation reported as primary study outcome.
Figure 4 SIGN score by disease manifestation reported as primary study outcome 1988-2013.
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disease, which whilst showing the greatest increase in
frequency, display one of the lowest incidences of SIGN-1
graded studies. There is currently no SIGN-1 graded
literature for management of neurological disease.
Again, it is perhaps most worrying that we observe a
relative decrease in the overall frequency of SIGN-1
graded papers over recent years, whilst the frequency of
lower quality papers is increasing. Our exclusion criteria
eliminated all SIGN-4 graded papers from review.
Given the deficit of published data to guide manage-
ment of the less common manifestations of BD and theFigure 5 SIGN score by decade 1988-2013.difficulty in performing large-scale randomized con-
trolled trials in rare diseases, clinicians may wish to
consider an alternative approach to generation of treat-
ment guidelines. Kobayashi et al. employed a modified
Delphi approach in developing guidelines for the diagno-
sis and management of intestinal BD [71]; this approach
involves development of consensus-based guidelines
through expert review of a selection of clinical state-
ments extracted from existing literature. It could be
argued that rather than being limited to the conven-
tional hierarchy of evidence as described by SIGN, this
approach allows a degree of objective assessment of
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excluded from published systematic reviews.
For rare diseases, consensus-based guidelines may
necessitate an international collaborative approach,
which can be facilitated through centres of excellence
[72]. In addition to “physical” centres of excellence in a
hospital setting, there is a growing recognition of the
value of virtual centres of excellence such as the
ORPHANET information portal [73].
We have made no comment on treatment efficacy or
side effects in our review. Hatemi et al. have previously
published detailed guidelines for the management of BD,
both in the form of evidence-based recommendations by
The European League Against Rheumatism (EULAR)
[74], and an accompanying systematic review of pub-
lished literature [70]. An independent management
algorithm was proposed in a wider review article by
Alpsoy in 2012 [75], and a Cochrane review of pharma-
cotherapy in BD was published in 2009 [76]. These
publications currently constitute the “gold standard” for
clinicians wishing to review treatment outcomes in exist-
ing literature, and provide a strong foundation on which
to base treatment decisions.
Clinicians should however be aware of the limitations
of these existing reviews: The EULAR review assessed
published literature only up to December 2006 and
Alpsoy up to 2010, whilst the Cochrane review (despite
being published later) included RCTs up to January
1998. Furthermore, whilst the Alpsoy review is a useful
resource, it makes no comment on the quality of refer-
enced studies, and relies on a mixture of primary data
and existing review articles. According to our inclusion
criteria, we have identified a further 21 studies which
were published since the EULAR recommendations were
finalized, and a further 16 RCTs since the termination of
the Cochrane review in 1998. Our review would suggest
an update of each of these existing sources is indicated.
We also note that these existing reviews assess only
pharmacological treatment options; high-quality evi-
dence is lacking in other modalities, however we found
evidence of ten studies reporting either primary or
secondary study outcomes of non-pharmacological ther-
apies. Whilst we acknowledge that surgery and other
invasive interventions should be reserved as a last resort,
we would urge clinicians to remember the impact of diet
and exercise on general health and well being of patients
with BD, and consider these areas which would benefit
from increased research activity.
This review is subject to a number of limitations: As dis-
cussed above, we have made no comment on the detail of
study outcomes, and have only categorized them in terms
of organ system investigated. We would recommend that
clinicians refer to the aforementioned publications by
Hatemi et al. for a comprehensive discussion of treatmentefficacy [70,74], but remain aware of the need for frequent
updates of published guidelines and be prepared to
consult original sources for themselves.
We may also have excluded a number of “useful” pub-
lications based on their small sample size; Behçet’s
Disease remains relatively rare in many populations [5]
and clinicians may struggle to generate large sample
sizes for clinical studies. They may however generate
interesting data on unusual treatment modalities in
small groups, and we would encourage clinicians to
assess these studies for themselves.
Conclusions
We conclude that evidence-based practice in BD is cur-
rently an ideal and not a feasible reality. To date, there
have been numerous studies on treatment for ocular and
mucocutaneous manifestations, however the availability
of evidence from large scale, randomized controlled tri-
als remains limited and we hope investigation continues
in these areas. There is an alarming shortage of research
investigating all other disease manifestations, and this is
an important area of unmet need that should be ad-
dressed through future work.
In addition, whilst current research is biased towards
newer biologic therapies, there is significant scope for
reappraisal of older agents that may prove to be benefi-
cial in certain situations following rigorous scientific
review.
Abbreviations
BD: Behçet’s disease; EBM: Evidence based medicine; EULAR: European
league against rheumatism; ISG: International study group; SIGN: Scottish
intercollegiate guideline network.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
BM, RM, HK, NJ and MM performed the initial scoping study to identify
papers for inclusion in this analysis and generated preliminary results on
which this manuscript is based. RB reviewed this initial scoping study,
finalized the list of papers for inclusion, completed the final analyses and
produced the manuscript. AD and PM conceived of the study, and
participated in its design and coordination and helped to draft the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
RB is funded by a Fight for Sight (UK) clinical fellowship. AD is funded by
Fight for Sight (UK) and Olivia’s Vision (UK).
Author details
1Centre for Translational Inflammation Research, School of Immunity and
Infection, College of Medical and Dental Sciences, Queen Elizabeth Hospital,
University of Birmingham, B15 2TT Birmingham, UK. 2Academic Unit of
Ophthalmology, University of Birmingham, Birmingham and Midland Eye
Centre, City Hospital, Birmingham, UK. 3University of Birmingham Medical
School, University of Birmingham, Birmingham, UK. 4Department of
Ophthalmology, Queen Elizabeth Hospital Birmingham, Edgbaston,
Birmingham, UK. 5Behçet’s Centre of Excellence, City Hospital, Sandwell &
West Birmingham Hospitals NHS Trust, Birmingham, UK.
Barry et al. Orphanet Journal of Rare Diseases 2014, 9:16 Page 9 of 10
http://www.ojrd.com/content/9/1/16Received: 5 December 2013 Accepted: 22 January 2014
Published: 30 January 2014References
1. Sackett D, Rosenberg W, Gray JA, Haynes RB, Richardson WS: Evidence
based medicine : what it is and what it isn’t. BMJ 1996, 312:71–72.
2. Fowkes FG, Fulton PM: Critical appraisal of published research:
introductory guidelines. BMJ 1991, 302:1136–1140.
3. Harbour R, Miller J: A new system for grading recommendations in
evidence based guidelines. BMJ 2001, 323:334–336.
4. Direskeneli H: Behçet’s disease: infectious aetiology, new autoantigens,
and HLA-B51. Ann Rheum Dis 2001, 60(11):996–1002.
5. Yazici Y, Yurdakul S, Yazici H: Behçet’s syndrome. Curr Rheumatol Rep 2010,
12(6):429–435.
6. Sakane T, Takeno M, Suzuki N, Inaba G: Behçet’s Disease. NEJM 1999,
341(17):1284–1291.
7. Alexoudi I, Kapsimali V, Vaiopoulos A, Kanakis M, Vaiopoulos G: Evaluation
of current therapeutic strategies in Behçet’s disease. Clin Rheumatol 2011,
30(2):157–163.
8. Arida A, Fragiadaki K, Giavri E, Sfikakis PP: Anti-TNF agents for Behcet's
Disease: analysis of published data on 369 patients. Semin Arthritis Rheum
2011, 41(1):61–70.
9. Wechsler B, Davatchi F, Mizushima Y, Hamza M, Dilsen N, Kansu E, Yazici H,
Barnes CG, Chamberlain MA, James DG, Lehner T, O’Duffy JD, Rigby AS,
Gregory J, Silman AJ: Criteria for diagnosis of Behçet’s disease.
Lancet 1990, 335:1078–1080.
10. Sakai T, Watanabe H, Kuroyanagi K, Akiyama G, Okano K, Kohno H, Tsuneoka
H: Health- and vision-related quality of life in patients receiving inflixi-
mab therapy for Behcet uveitis. Br J Ophthalmol 2013, 97(3):338–342.
11. Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V,
Androudi S: Secukinumab in the treatment of noninfectious uveitis:
results of three randomized, controlled clinical trials. Ophthalmology
2013, 120(4):777–787.
12. Yoshida A, Kaburaki T, Okinaga K, Takamoto M, Kawashima H, Fujino Y:
Clinical background comparison of patients with and without ocular
inflammatory attacks after initiation of infliximab therapy.
Jpn J Ophthalmol 2012, 56(6):536–543.
13. Okada AA, Goto H, Ohno S, Mochizuki M: Ocular Behçet’s Disease
Research Group Of Japan. Multicenter study of infliximab for refractory
uveoretinitis in Behçet disease. Arch Ophthalmol 2012, 130(5):592–598.
14. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis
PP: A single infliximab infusion vs corticosteroids for acute panuveitis
attacks in Behçet’s disease: a comparative 4-week study. Rheumatology
2011, 50(3):593–597.
15. Giardina A, Ferrante A, Ciccia F, Vadalà M, Giardina E, Triolo G: One year
study of efficacy and safety of infliximab in the treatment of patients
with ocular and neurological Behçet’s disease refractory to standard
immunosuppressive drugs. Rheumatol Int 2011, 31(1):33–37.
16. Saadoun D, Wechsler B, Terrada C, Hajage D, Le Thi HD, Resche-Rigon M,
Cassoux N, Le Hoang P, Amoura Z, Bodaghi B, Cacoub P: Azathioprine in
severe uveitis of Behçet’s disease. Arthritis Care Res 2010,
62(12):1733–1738.
17. Inanc MT, Kalay N, Heyit T, Ozdogru I, Kaya MG, Dogan A, Duran M,
Kasapkara HA, Gunebakmaz O, Borlu M, Yarlıoglues M, Oguzhan A: Effects
of atorvastatin and lisinopril on endothelial dysfunction in patients with
Behçet’s disease. Echocardiography 2010, 27(8):997–1003.
18. Chams-Davatchi C, Barikbin B, Shahram F, Nadji A, Moghaddassi M, Yousefi
M, Davatchi F: Pimecrolimus versus placebo in genital aphthous ulcers of
Behcet’s disease: a randomized double-blind controlled trial. Int J Rheum
Dis 2010, 13(3):253–258.
19. Davatchi F, Shams H, Rezaipoor M, Sadeghi-Abdollahi B, Shahram F, Nadji A,
Chams-Davatchi C, Akhlaghi M, Faezi T, Naderi N: Rituximab in intractable
ocular lesions of Behcet’s disease; randomized single-blind control study
(pilot study). Int J Rheum Dis 2010, 13(3):246–252.
20. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M:
Comparison of infliximab versus ciclosporin during the initial 6-month
treatment period in Behçet disease. Br J Ophthalmol 2010, 94(3):284–288.
21. Arabaci T, Kara C, Ciçek Y: Relationship between periodontal parameters
and Behçet’s disease and evaluation of different treatments for oral
recurrent aphthous stomatitis. J Periodontal Res 2009, 44(6):718–725.22. Kiliç H, Zeytin HE, Korkmaz C, Mat C, Gül A, Coşan F, Dinç A, Simşek I, Süt N,
Yazici H: Low-dose natural human interferon-alpha lozenges in the
treatment of Behçet’s syndrome. Rheumatology 2009, 48(11):1388–1391.
23. Kim WH, Choi D, Kim JS, Ko YG, Jang Y, Shim WH: Effectiveness and safety
of endovascular aneurysm treatment in patients with vasculo-Behçet
disease. J Endovasc Ther 2009, 16(5):631–636.
24. Sun A, Wang YP, Chia JS, Liu BY, Chiang CP: Treatment with levamisole
and colchicine can result in a significant reduction of IL-6, IL-8 or
TNF-alpha level in patients with mucocutaneous type of Behcet’s
disease. J Oral Pathol Med 2009, 38(5):401–405.
25. Karacayli U, Mumcu G, Simsek I, Pay S, Kose O, Erdem H, Direskeneli H,
Gunaydin Y, Dinc A: The close association between dental and
periodontal treatments and oral ulcer course in behcet’s disease: a
prospective clinical study. J Oral Pathol Med 2009, 38(5):410–415.
26. Köse O, Dinç A, Simşek I: Randomized trial of pimecrolimus cream plus
colchicine tablets versus colchicine tablets in the treatment of genital
ulcers in Behçet’s disease. Dermatology 2009, 218(2):140–145.
27. Davatchi F, Sadeghi Abdollahi B, Tehrani Banihashemi A, Shahram F, Nadji
A, Shams H, Chams-Davatchi C: Colchicine versus placebo in Behçet’s
disease: randomized, double-blind, controlled crossover trial.
Mod Rheumatol 2009, 19(5):542–549.
28. Tabbara KF, Al-Hemidan AI: Infliximab effects compared to conventional
therapy in the management of retinal vasculitis in Behçet disease. Am J
Ophthalmol 2008, 146(6):845–850.
29. Kump LI, Moeller KL, Reed GF, Kurup SK, Nussenblatt RB, Levy-Clarke GA:
Behçet’s disease: comparing 3 decades of treatment response at the
National Eye Institute. Can J Ophthalmol 2008, 43(4):468–472.
30. Protogerou AD, Sfikakis PP, Stamatelopoulos KS, Papamichael C, Aznaouridis
K, Karatzis E, Papaioannou TG, Ikonomidis I, Kaklamanis P, Mavrikakis M,
Lekakis J: Interrelated modulation of endothelial function in Behcet’s
disease by clinical activity and corticosteroid treatment. Arthritis Res Ther
2007, 9(5):R90.
31. Tasli L, Mat C, De Simone C, Yazici H: Lactobacilli lozenges in the
management of oral ulcers of Behçet’s syndrome. Clin Exp Rheumatol
2006, 24(3):S83–S86. Erratum in: Clin Exp Rheumatol. 2007, 25(3):507-8.
32. Sharquie KE, Najim RA, Al-Dori WS, Al-Hayani RK: Oral zinc sulfate in the
treatment of Behcet’s disease: a double blind cross-over study.
J Dermatol 2006, 33(8):541–546.
33. Mat C, Yurdakul S, Uysal S, Gogus F, Ozyazgan Y, Uysal O, Fresko I, Yazici H:
A double-blind trial of depot corticosteroids in Behçet’s syndrome.
Rheumatology 2006, 45(3):348–352.
34. Al-Waiz MM, Sharquie KE, A-Qaissi MH, Hayani RK: Colchicine and
benzathine penicillin in the treatment of Behçet disease: a case
comparative study. Dermatol Online J 2005, 11(3):3.
35. Ahn JK, Chung H, Yu HG: Vitrectomy for persistent panuveitis in Behçet’s
disease. Ocul Immunol Inflamm 2005, 13(6):447–453.
36. Melikoglu M, Fresko I, Mat C, Ozyazgan Y, Gogus F, Yurdakul S, Hamuryudan
V, Yazici H: Short-term trial of etanercept in Behçet’s disease: a double
blind, placebo controlled study. J Rheumatol 2005, 32(1):98–105.
37. Kötter I, Vonthein R, Zierhut M, Eckstein AK, Ness T, Günaydin I, Grimbacher
B, Blaschke S, Peter HH, Stübiger N: Differential efficacy of human
recombinant interferon-alpha2a on ocular and extraocular manifesta-
tions of Behçet disease: results of an open 4-center trial. Semin Arthritis
Rheum 2004, 33(5):311–319.
38. Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG,
Papaefthimiou S, Markomichelakis N: Infliximab for recurrent,
sight-threatening ocular inflammation in Adamantiades-Behçet disease.
Ann Intern Med 2004, 140(5):404–406.
39. Nitecki SS, Ofer A, Karram T, Schwartz H, Engel A, Hoffman A: Abdominal
aortic aneurysm in Behçet’s disease: new treatment options for an old
and challenging problem. Isr Med Assoc J 2004, 6(3):152–155.
40. Yu P, Bai H, Chen L, Zhang W, Xia Y, Wu G: Clinical study on therapeutic effect
of acupuncture on Behcet’s disease. J Tradit Chin Med 2003, 23(4):271–273.
41. Lashay AR, Rahimi A, Chams H, Davatchi F, Shahram F, Hatmi ZN, Khalkhali
H, Beigi B: Evaluation of the effect of acetazolamide on cystoid macular
oedema in patients with Behcet’s disease. Eye 2003, 17(6):762–766.
42. Krause L, Turnbull JR, Torun N, Pleyer U, Zouboulis CC, Foerster MH:
Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet’s
disease. Adv Exp Med Biol 2003, 528:511–519.
43. Matsuda T, Ohno S, Hirohata S, Miyanaga Y, Ujihara H, Inaba G, Nakamura S,
Tanaka S, Kogure M, Mizushima Y: Efficacy of rebamipide as adjunctive
Barry et al. Orphanet Journal of Rare Diseases 2014, 9:16 Page 10 of 10
http://www.ojrd.com/content/9/1/16therapy in the treatment of recurrent oral aphthous ulcers in patients
with Behçet’s disease: a randomised, double-blind, placebo-controlled
study. Drugs R D 2003, 4(1):19–28.
44. Sharquie KE, Najim RA, Abu-Raghif AR: Dapsone in Behçet’s disease: a
double-blind, placebo-controlled, cross-over study. J Dermatol 2002,
29(5):267–279.
45. Mudun BA, Ergen A, Ipcioglu SU, Burumcek EY, Durlu Y, Arslan MO: Short-
term chlorambucil for refractory uveitis in Behcet’s disease. Ocul Immunol
Inflamm 2001, 9(4):219–229.
46. Yurdakul S, Mat C, Tüzün Y, Ozyazgan Y, Hamuryudan V, Uysal O, Senocak
M, Yazici H: A double-blind trial of colchicine in Behçet’s syndrome.
Arthritis Rheum 2001, 44(11):2686–2692.
47. Adler YD, Mansmann U, Zouboulis CC: Mycophenolate mofetil is
ineffective in the treatment of mucocutaneous Adamantiades-Behçet’s
disease. Dermatology 2001, 203(4):322–324.
48. Fujino Y, Joko S, Masuda K, Yagi I, Kogure M, Sakai J, Usui M, Kotake S,
Matsuda H, Ikeda E, Mochizuki M, Nakamura S, Ohno S: Ciclosporin
microemulsion preconcentrate treatment of patients with Behçet’s
disease. Jpn J Ophthalmol 1999, 43(4):318–326.
49. Alpsoy E, Er H, Durusoy C, Yilmaz E: The use of sucralfate suspension in
the treatment of oral and genital ulceration of Behçet disease: a
randomized, placebo-controlled, double-blind study. Arch Dermatol 1999,
135(5):529–532.
50. Kosar A, Haznedaroglu S, Karaaslan Y, Büyükasik Y, Haznedaroglu IC, Ozath
D, Sayinalp N, Ozcebe O, Kirazli S, Dündar S: Effects of interferon-alpha2a
treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis
factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and
E-selectin in Behçet’s disease. Rheumatol Int 1999, 19(1-2):11–14.
51. Zouboulis CC, Orfanos CE: Treatment of Adamantiades-Behçet disease
with systemic interferon alfa. Arch Dermatol 1998, 134(8):1010–1016.
52. Hamuryudan V, Mat C, Saip S, Ozyazgan Y, Siva A, Yurdakul S,
Zwingenberger K, Yazici H: Thalidomide in the treatment of the
mucocutaneous lesions of the Behçet syndrome. A randomized,
double-blind, placebo-controlled trial. Ann Intern Med 1998,
128(6):443–450.
53. Calgüneri M, Ertenli I, Kiraz S, Erman M, Celik I: Effect of prophylactic
benzathine penicillin on mucocutaneous symptoms of Behçet’s disease.
Dermatology 1996, 192(2):125–128.
54. Sakane T, Mochizuki M, Inaba G, Masuda K: A phase II study of FK506
(tacrolimus) on refractory uveitis associated with Behçet’s disease and
allied conditions. Ryumachi 1995, 35(5):802–813.
55. Moral F, Hamuryudan V, Yurdakul S, Yazici H: Inefficacy of azapropazone in
the acute arthritis of Behçet’s syndrome: a randomized, double blind,
placebo controlled study. Clin Exp Rheumatol 1995, 13(4):493–495.
56. Gardner-Medwin JM, Smith NJ, Powell RJ: Clinical experience with
thalidomide in the management of severe oral and genital ulceration in
conditions such as Behçet’s disease: use of neurophysiological studies to
detect thalidomide neuropathy. Ann Rheum Dis 1994, 53(12):828–832.
57. Hamuryudan V, Moral F, Yurdakul S, Mat C, Tüzün Y, Ozyazgan Y, Direskeneli
H, Akoglu T, Yazici H: Systemic interferon alpha 2b treatment in Behçet’s
syndrome. J Rheumatol 1994, 21(6):1098–1100.
58. Hayasaka S, Kawamoto K, Noda S, Kodama T: Visual prognosis in patients
with Behçet’s disease receiving colchicine, systemic corticosteroid or
cyclosporin. Ophthalmologica 1994, 208(4):210–213.
59. Ozyazgan Y, Yurdakul S, Yazici H, Tüzün B, Işçimen A, Tüzün Y, Aktunç T,
Pazarli H, Hamuryudan V, Müftüoğlu A: Low dose cyclosporin A versus
pulsed cyclophosphamide in Behçet’s syndrome: a single masked trial. Br
J Ophthalmol 1992, 76(4):241–243.
60. Hamuryudan V, Yurdakul S, Rosenkaimer F, Yazici H: Inefficacy of topical
alpha interferon in the treatment of oral ulcers of Behçet’s syndrome: a
randomized, double blind trial. Br J Rheumatol 1991, 30(5):395–396.
61. Benamour S, Bennis R, Messoudi M, Zaoui A, Amor B: Desensitization by
autologous saliva and Behçet’s disease. Rev Med Interne 1991,
12(5):339–342.
62. Elidan J, Levi H, Cohen E, BenEzra D: Effect of cyclosporine A on the
hearing loss in Behçet’s disease. Ann Otol Rhinol Laryngol 1991,
100(6):464–468.
63. Kazokoglu H, Saatçi O, Cuhadaroglu H, Eldem B: Long-term effects of
cyclophosphamide and colchicine treatment in Behçet’s disease.
Ann Ophthalmol 1991, 23(4):148–151.64. Simsek H, Dundar S, Telatar H: Treatment of Behçet disease with
indomethacin. Int J Dermatol 1991, 30(1):54–57.
65. Yazici H, Pazarli H, Barnes CG, Tüzün Y, Ozyazgan Y, Silman A, Serdaroğlu S,
Oğuz V, Yurdakul S, Lovatt GE, Yazici B, Somani S, Müftüoğlu A: A
controlled trial of azathioprine in Behçet’s syndrome. N Engl J Med 1990,
322(5):281–285.
66. Hamuryudan V, Yurdakul S, Serdaroglu S, Tüzün Y, Rosenkaimer F, Yazici H:
Topical alpha interferon in the treatment of oral ulcers in Behçet’s
syndrome: a preliminary report. Clin Exp Rheumatol 1990, 8(1):51–54.
67. Masuda K, Nakajima A, Urayama A, Nakae K, Kogure M, Inaba G:
Double-masked trial of cyclosporin versus colchicine and long-term
open study of cyclosporin in Behçet’s disease. Lancet 1989,
1(8647):1093–1096.
68. Davies UM, Palmer RG, Denman AM: Treatment with acyclovir does not
affect orogenital ulcers in Behçet’s syndrome: a randomized
double-blind trial. Br J Rheumatol 1988, 27(4):300–302.
69. BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, Harris W:
Evaluation of conventional therapy versus cyclosporine A in Behçet’s
syndrome. Transplant Proc 1988, 20(3 Suppl 4):136–143.
70. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman
MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger
N, Yurdakul S, Yazici H: Management of Behçet disease: a systematic
literature review for the European League Against Rheumatism
evidence-based recommendations for the management of Behçet
disease. Ann Rheum Dis 2009, 68(10):1528–1534.
71. Kobayashi K, Ueno F, Bito S, Iwao Y, Fukushima T, Hiwatashi N, Masahiro I,
Bun-Ei I, Takahide M, Toshiyuki M, Takayuki M, Akira S, Mitsuhiro T, Toshifumi
H: Development of consensus statements for the diagnosis and
management of intestinal Behçet’s disease using a modified Delphi
approach. J Gastroenterol 2007, 42:737–745.
72. Taylor CM, Karet Frankl FE: Developing a strategy for the management of
rare diseases. BMJ 2012, 344:e2417.
73. Rath A, Olry A, Dhombres F, Brandt MM, Urbero B, Ayme S: Representation
of rare diseases in health information systems: the orphanet approach
to serve a wide range of end users. Hum Mutat 2012, 33(5):803–808.
74. Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, Houman
MH, Kotter I, Olivieri I, Salvarani C, Sfikakis PP, Siva A, Stanford MR, Stubiger
N, Yurdakul S, Yazici H: EULAR recommendations for the management of
Behçet disease. Ann Rheum Dis 2008, 67(12):1656–1662.
75. Alpsoy E: New evidence-based treatment approach in Behçet’s disease.
Patholog. Res. Int. 2012, 2012:871019.
76. Saenz A, Ausejo M, Shea B, Ga W, Welch V, Tugwell P: Pharmacotherapy for
Behçet’s syndrome. Cochrane Database Syst Rev 1998(3 Suppl 4): . Art No.:
CD001084. DOI: 10.1002/14651858.CD001084.
doi:10.1186/1750-1172-9-16
Cite this article as: Barry et al.: Evidence-based practice in Behçet’s
disease: identifying areas of unmet need for 2014. Orphanet Journal of
Rare Diseases 2014 9:16.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
